NAG (N-acetyl-L-glutamate), the essential allosteric activator of the first urea cycle enzyme, CPSI (carbamoyl phosphate synthetase I), is a key regulator of this crucial cycle for ammonia detoxification in animals (including humans). Automated cavity searching and flexible docking have allowed identification of the NAG site in the crystal structure of human CPSI C-terminal domain. The site, a pocket lined by invariant residues and located between the central β-sheet and two α-helices, opens at the β-sheet C-edge and is roofed by a three-residue lid. It can tightly accommodate one extended NAG molecule having the δ-COO − at the pocket entry, the α-COO − and acetamido groups tightly hydrogen bonded to the pocket, and the terminal methyl of the acetamido substituent surrounded by hydrophobic residues. This binding mode is supported by the observation of reduced NAG affinity upon mutation of NAG-interacting residues of CPSI (recombinantly expressed using baculovirus/insect cells); by the fine-mapping of the N-chloroacetyl-L-glutamate photoaffinity labelling site of CPSI; and by previously established structureactivity relationships for NAG analogues. The location of the NAG site is identical to that of the weak bacterial CPS activator IMP (inosine monophosphate) in Escherichia coli CPS, indicating a common origin for these sites and excluding any relatedness to the binding site of the other bacterial CPS activator, ornithine. Our findings open the way to the identification of CPSI deficiency patients carrying NAG site mutations, and to the possibility of tailoring the activator to fit a given NAG site mutation, as exemplified here with N-acetyl-L( + − )-β-phenylglutamate for the W1410K CPSI mutation.
INTRODUCTION
CPSs [CP (carbamoyl phosphate) synthetases] are complex multidomain enzymes found in virtually all organisms [1] . These allosterically regulated controlling enzymes synthesize CP, a crucial compound for life, in the first committed step of the routes of synthesis of pyrimidines, arginine and, in ureotelic vertebrates (mainly amphibians and mammals), urea. In these latter animals (including humans), CPSI, the enzyme that catalyses the first step of the urea cycle, has an absolute requirement for the allosteric activator NAG (N-acetyl-L-glutamate) [2, 3] . NAG plays a key role in controlling the flow of nitrogen through the urea cycle [4] [5] [6] , as exemplified by the deficiency of the enzyme making NAG, NAG synthase, a deficiency that generally causes severe neonatal hyperammonaemia [7] due to secondary CPSI deficiency. Interestingly, there is a highly effective substitutive therapy for NAG synthase deficiency, by using the deacylaseresistant NAG analogue NCG (N-carbamoyl-L-glutamate, also called carglumic acid; proprietary drug name, Carbaglu ® ) [7, 8] .
Although CPSI activation by NAG has been known for some time [2] , and despite the use of NCG in the treatment of NAG synthase deficiency for nearly 30 years [7, 8] , the CPSI NAG site has remained uncharacterized. Such characterization is a requisite for understanding the mechanism of the extreme allosteric activation of CPSI by NAG, and would have practical interest for identifying CPSI deficiency resulting from NAG site mutations. The patients carrying these mutations might be amenable to treatment with very high doses of NCG or with NCG analogues tailored to bind better to the mutant form of the site.
Until now, the only existing physical information about the NAG site was its gross localization at the CPSI C-terminal domain, deduced from the observation that this domain of ∼ 16 kDa is the only part of CPSI (a polypeptide of ∼ 160 kDa) that is photoaffinity labelled by the photoactivatable NAG analogue [ 14 C]ClNAG (N-chloroacetyl-L-[ 14 C]glutamate) [9] . In fact, this C-terminal domain is called the allosteric or regulatory domain in all types of CPS because it is believed to be involved exclusively in effector binding, relaying the regulatory information to the catalytic domains (two homologous 40 kDa domains that catalyse the phosphorylations of bicarbonate and carbamate) [10] . The evidence for this conclusion was based on photoaffinity labelling studies, first performed with CPSI [9] , and then with eCPS (Escherichia coli CPS) [11] [12] [13] [14] [15] ; on domain-deletion and domainexchange experiments carried out with eCPS and with CPSII from hamster CAD [16, 17] (a trifunctional protein composed of carbamoyl phosphate synthetase II, aspartate transcarbamylase and dihydro-orotase, which catalyses the three initial steps of pyrimidine biosynthesis); on the observation that phosphorylation of this domain of hamster CAD decreased UTP inhibition of CPSII [18] ; and on the determination of the crystal structures of eCPS in complex with the inhibitor UMP [19] or with the activators ornithine [20] or IMP (inosine monophosphate) [21] . However, the structural information gathered on eCPS has not allowed study of where and how NAG binds to CPSI, given the poor sequence identity (∼ 20 %) between the allosteric domains of CPSI and eCPS [10] , and because of the uncertainties on whether the activations of both enzymes occur with similar mechanisms, since eCPS is active in the absence of its effectors [22] , whereas CPSI is essentially inactive when NAG is not present [3] . In addition, the two activators of eCPS, ornithine and IMP, bind to different sites [20, 21] , raising the question of which one of these sites, if any, would be analogous to the NAG site if the allosteric domains of eCPS and CPSI were similar.
A unique opportunity for identifying the NAG site in CPSI was provided recently when, as a part of a high-throughput structural genomics/proteomics effort, the crystal structure of the C-terminal domain of hCPSI (human CPSI), generated in isolated form in a cell-free protein expression system, was deposited in the PDB [23] . Using cavity searching and flexible docking we can now identify the binding site for NAG in this structure. From the shape of the binding pocket and from the chemical characteristics of the residues lining this site, we define unambiguously the way in which NAG binds to CPSI. This binding mode fits closely the expectations derived from previous studies on structure-activity relationships for NAG analogues [2, 24, 25] , and is supported by experimental evidence reported in the present work: the finemapping of the [ 14 C]ClNAG photoaffinity-labelling site within CPSI, and the results of site-directed mutagenesis experiments involving residues predicted to interact with the bound activator. The implications of our findings for the diagnosis and treatment of CPSI deficiency are discussed, highlighting with one experimental example the possibility of using modified NAG analogues to improve activation of defective CPSI forms carrying specific mutations in the NAG site. Finally, the proposed NAG-binding mode is compared with those of the bacterial activators IMP and ornithine, discussing possible evolutionary origins of the NAG site.
EXPERIMENTAL

Identification of the NAG site and docking of the NAG molecule
The structure deposited in the PDB as file 2YVQ [23] , corresponding to the C-terminal domain of hCPS (residues 1343-1478), was analysed for the presence of cavities with VOIDOO (version 3.3.4) [26] . NAG was docked into the pocket identified with VOIDOO using the GOLD (version 4.0.1) package [27] , a genetic algorithm for docking flexible ligands into protein-binding sites that has been optimized for the prediction of ligandbinding positions. Docking calculations were unrestrained and used the GoldScore fitness function. The preference of NAG for binding in this pocket was confirmed by GOLD docking runs involving the entire hCPS C-terminal domain or by docking NAG into alternative hCPS C-terminal domain cavities. Trp  1410 and   the overlying Phe  1445 and Gln  1413 residues were allowed to rotate  freely yielded a highly stable binding pose in which the Trp   1410   ring had flipped 180 • while maintaining the stacking interaction with the neighbouring Phe 1445 and keeping a commonly observed side chain conformation [28] . Subsequent GOLD calculations using this alternative protein conformation led to very good NAG docking scores, with almost total convergence (95 %) of the NAG-binding poses [19 of 20 solutions with an rmsd (root mean square deviation) conformational deviation of 1.35 Å (1 Å = 0.1 nm) or less; see below]. The final hCPS-NAG model was generated by refining further the best GOLD solution by restrained energy minimization using the ff03 force field [29] of AMBER 8.0 [30] , and a generalized Born model for solvent simulation. This last minimization used as restraints the protein-NAG hydrogen bonds detected in the converged GOLD binding poses (see below).
Structural analysis and preparation of Figures
Structural superimpositions were performed with the LSQKAB option of the CCP4 suite [31] . Solvent accessibility (probe radius, 1.4 Å) of residues within the eCPS (bound to IMP; PDB number 1CE8 [21] ) and hCPS (PDB number 2YVQ [23] ) structures was calculated with the AREAIMol program of CCP4 [31] . Surface potential was calculated with GRASP [32] . Multiple sequence alignments were prepared with CLUSTALW [33] , using default parameters. Figures depicting protein structures were prepared with PyMOL (DeLano Scientific; http://www.pymol.org).
Fine-mapping of the rCPSI (rat CPSI) photoaffinity-labelling site
Purification of rat liver CPSI, synthesis of ClNAG (unlabelled or labelled with [ 14 C] in the glutamate moiety) and photoaffinity labelling of the enzyme have been reported previously [9] . Limited proteolysis with V8 staphylococcal protease, HPLC isolation of the resulting 18.9 kDa C-terminal labelled fragment, and electrophoresis, fluorography and Edman sequencing were as previously reported for [
14 C]UMP-labelled eCPS [11] . Digestion of the 18.9 kDa labelled fragment with either CNBr [35] or trypsin (alone or followed by the V8 protease under conditions at which the V8 protease cleaves only at glutamate residues [12, 36] ) have also been previously reported for [ 14 C]UMP-labelled eCPS [12] . o-Iodosobenzoic acid cleavage of the 18.9 kDa labelled fragment was carried out in the dark at 21
• C for 24 h according to [37] , in a volume of 50 μl. The reaction was terminated with 1 μl of 1 mM dithioerythritol and the mixture was desalted by centrifugal gel filtration [38] through a 1 ml Sephadex G-25 column equilibrated with 50 % (v/v) acetonitrile/0.1 % (v/v) trifluoroacetic acid. After removal of the solvent by freeze-drying, the residue was subjected to SDS/urea phosphate PAGE using a formulation [12] suitable for small peptides. For determination of the mass of tryptic or tryptic/V8-protease fragments, the Sephacryl S200-SDS gel-filtration technique [12] For MS analysis, the enzyme was subjected as described above to UV irradiation in the presence of either ClNAG (experimental irradiation) or NAG (control irradiation) followed by limited proteolysis with the V8 protease. After SDS/PAGE, the Coomassie-stained 18.9 kDa band corresponding to the Cterminal domain of the enzyme from the experimental and control samples was excised from each gel and was subjected to peptide fingerprinting using trypsin (Promega) [39] and MALDI-TOF (matrix-assisted laser-desorption ionization-time-of-flight) MS analysis in a 4700 Proteomics Analyzer (Applied Biosystems) used in linear mode, with concomitant MS/MS (tandem MS) analysis of relevant peaks to acquire sequence information. The MS and MS/MS information were analysed with MASCOT [40] . The MS analysis was carried out by the Proteomics Core Facility of the Centro de Investigación Príncipe Felipe (CIPF Valencia)-Proteored (Genoma España).
Recombinant rCPSI production and mutagenesis
Recombinant rCPSI was produced using a commercial kit (Bacto-Bac ® Baculovirus Expression System; Invitrogen). The rCPSI cDNA carried by pHN3491 [41] was subcloned into the pFastBac-HTA vector provided in the kit, using standard techniques for DNA manipulation and for engineering the cDNA to replace the CPSI mitochondrial targeting sequence by the 6 × His, 28-residue, N-terminal tag MSYYHHHHHHDYDIPTTENLY-FQGAMDP, provided by the vector. After transformation of E. coli Max Efficiency DH10Bac cells (Invitrogen), the recombinant bacmid was recovered and transfected into Sf9 insect cells using Cellfectin. The resulting virus was then used to infect Sf9 cells. The best expression (monitored by SDS/PAGE) was obtained at a virus-to-cell ratio of 2, by incubation at 27
• C for 65 h. Subsequent steps were at 4
• C. After centrifugation of a 50 ml culture, the cells were suspended in 3 ml of 50 mM glycyl-glycine, pH 7, 20 mM KCl, 20 % glycerol, 0.1 % Triton X-100, 5 mM imidazole, 0.1 % histidine-tagged specific protease inhibitor mixture and 5 μM cysteine protease irreversible inhibitor E-64 (the last two components were from Sigma). The cell suspension was frozen (in liquid nitrogen) and thawed twice, then centrifuged, and the supernatant was mixed with 0.5 ml packed TALON resin (Clontech) equilibrated in the same solution without Triton X-100 or protease inhibitors. After 30 min gentle end-to-end mixing and two washes with 5 ml of equilibration solution containing 10 mM imidazole, the resin was packed in a column and was eluted with equilibration solution containing 0.15 M imidazole. Dithiothreitol (1 mM) was added to the column effluent, and the fractions containing CPSI (monitored by SDS/PAGE) were pooled and concentrated to > 1 mg of protein/ml by centrifugal ultrafiltration (100 kDa cut-off Amicon Ultra; Millipore).
Site-directed mutagenesis was performed by the overlapping extension method using a commercial kit (QuikChange; Stratagene), the pFastBac-HTA vector containing the CPSI cDNA as template, a high-fidelity thermostable DNA polymerase (Pfu Turbo from Stratagene) and the appropriate mutagenic forward and reverse oligonucleotides (see Supplementary Table S1 at http://www.BiochemJ.org/bj/424/bj4240211add.htm). Mutations were either to alanine (T1394A) or to residues expected to cause the smallest possible structural change (N1437D, N1440D and T1391V). The W1410K mutation introduces the residue found in bacterial CPSs (see Supplementary Figure S1 at http://www.BiochemJ.org/bj/424/bj4240211add.htm). Mutant plasmids were sequenced to assure the respective presence and absence of the desired and unwanted mutations. Production of the mutant proteins by the insect cells and mutant protein purification were as for the wild-type enzyme.
Enzyme activity assay
CPSI activity was assayed at 37
• C in a solution containing 50 mM glycyl-glycine, pH 7.4, 0.1 M KCl, 0.1 M NH 4 Cl, 5 mM ATP, 7 mM MgSO 4 , 20 mM KHCO 3 , 1 mM dithiothreitol, 5 mM Lornithine, 10 units/ml ornithine transcarbamylase (Sigma) and NAG as indicated or, when indicated, Phe-NAG [N-acetyl-L(+ − )-β-phenylglutamate] (prepared as described in [25] ), determining citrulline after 10 min, and, when indicated, ADP [3, 42] . Results of at least duplicate assays were fitted to hyperbolic kinetics with GraphPad Prism (GraphPad Software).
Other assays
CD spectra in the far-UV region (195-250 nm) were obtained at 4
• C with a Jasco 810 spectropolarimeter in 0.2 ml of 20 mM Tris/HCl, pH 7.4, 20 mM KCl, 20 % glycerol, 0.5 mM dithiothreitol and 1-2 μM protein in a 0.1 cm-pathlength cell. Each spectrum was the average of ten scans. Protein was determined by the Bradford assay [43] using BSA as standard.
RESULTS AND DISCUSSION
Proposed site and mode of NAG binding in CPSI
Since the structure of the C-terminal domain of hCPS (PDB file 2YVQ [23] ) was obtained using the acellularly produced isolated domain without the natural context provided by the remaining domains of the protein, there could be doubts on whether the structure is the genuine one or an artefact. The latter possibility appears to be excluded by the observation that, despite the poor sequence identity with the allosteric domain of eCPS (20 % identity; see Supplementary Figure S1 ), the structure of the two domains is virtually identical (rmsd of 1. A previous study [44] demonstrated the binding of one NAG molecule per subunit of rat liver CPSI. Using the hCPS Cterminal domain structure [23] , and utilizing automated cavitysearching [26] and ligand-docking [27] algorithms, we only detected one pocket containing the approximate dimensions required to accommodate the NAG molecule ( Figures 1A and 1B) . The pocket, opening at the sheet C-edge, is located between the β sheet and the helical layer containing helices 3 and 4 ( Figure 1A ). In this pocket, the indolic ring of Trp 1410 , along with Phe 1445 and Lys 1444 , forms a lid separating the cavity from the surrounding solution ( Figure 1B) . Initial docking experiments indicated that, in the rotamer observed in the crystal structure of the empty pocket, the Trp 1410 side chain would hamper optimal fitting of NAG inside the cavity. Thus, when flexibility of the side chains of Trp 1410 and the overlying Phe 1445 and Gln 1413 residues was allowed, a highly stable binding pose was detected ( Figure 1D ). In this conformation, the Trp 1410 aromatic ring has flipped 180 o around the Cβ-Cγ bond relative to the conformation observed in the crystal structure of the hCPS C-terminal domain, while maintaining the stack with Phe 1445 ( Figure 1D ). This alternative Trp 1410 side-chain conformation is commonly observed in proteins [28] . Subsequent calculations using this alternative protein conformation led to much better NAG docking scores and to almost total convergence (95 %) of the NAG-binding poses ( Figure 1D ).
In the converged solutions ( Figure 1E ), the NAG molecule adopts a largely extended conformation and places its α-COO Figure 1E ), whereas its carbonyl group points towards the Asn 1437 side-chain amide, with which it forms a hydrogen bond ( Figure 1F ). The -OH groups of Thr 1391 and Thr 1394 are close to the outward-facing NAG δ-COO − , donating hydrogen bonds to it ( Figure 1F ). The positive surface potential at the pocket entry (estimated with GRASP [32] ; not illustrated) fits the binding of the negatively charged δ-COO − . Finally, the C β atom of the glutamate side chain also faces outwards, making contacts with the indolic ring of Trp 1410 ( Figure 1E ). These proposed NAG-interacting residues are strictly conserved in CPSs, with some of them (Trp  1410 , Asn   1440 and Asn 1449 , see Supplementary Figure S1 ) being conserved exclusively in NAG-sensitive CPSs, supporting the functional importance of this pocket and its implication in NAG binding.
The proposed mode of NAG binding agrees with prior structure-activity studies with NAG analogues A structure-activity study [25] concluded that NAG binds, with its glutamate moiety extended in a low-energy conformation, to a CPSI site containing the subsites for the α-COO − and for the acetamido group of NAG fixed relative to each other (deduced from the abolition of binding by adding a methylene group between the asymmetric C atom and the α-COO − of NAG [25] ), whereas the subsite for the δ-COO − appeared less constrained. All these traits are reflected in our model in the present study for NAG binding: the NAG molecule is extended, the subsites for the α-COO − and acetamido groups involve the internal regions of the pocket and the δ-COO − binds at the pocket opening ( Figure 1E ), which should offer an sterically less constrained context. Prior observations that thiocarbamoylglutamate does not activate CPSI [2] , but that N-acetoxyglutarate is an activator [24] , also agree with our present proposal ( Figures 1E and 1F) , since in our model the O atom of the NAG acetamido group is appropriately placed for forming one hydrogen bond with the enzyme. The inactive N-acetyl, N-methyl-L-glutamate analogue [25] would be unable to form the proposed hydrogen bond between the αN and Thr 1391 ( Figures 1E and 1F ), in addition to causing steric clash with the site. The inability of N-butyryl-L-glutamate [2] to activate CPSI parallels the observation of lack of space within the binding pocket ( Figure 1E ) to accommodate the N-butyryl instead of the N-acetyl group. In contrast, little reshuffling would be needed for replacing the N-acetyl group of NAG by the modestly larger N-propionyl or N-chloroacetyl groups and, indeed, the corresponding NAG analogues are quite good activators of CPSI [25] . The structure also accounts for the binding of NCG, given the similar size and overall shape of the carbamoyl and acetyl groups. However, the higher polarity and different geometry of the NH 2 in the carbamoyl group relative to the CH 3 of the acetyl substituent would be expected to impair somewhat the interactions with the hydrophobic cavity that hosts this methyl group of NAG, explaining the ∼ 10-fold lesser affinity of CPSI for NCG relative to NAG [25] . The importance of the hydrophobic interactions with the methyl group are illustrated by the observation that the affinity of CPSI for N-formyl-L-glutamate, which lacks this methyl group, is two orders of magnitude lower than for NAG [25] . Finally, in agreement with the prediction from our model that the glutamate side chain of NAG faces towards the pocket entry, and, in particular, that the NAG C β atom is partially exposed and contacts the pocket roof residue Trp 1410 , the NAG analogue with a phenyl substituent at the C β , Phe-NAG, was a good CPSI activator [25] . Thus the extra phenyl group of Phe-NAG can be accommodated in this outward-facing part of the site, possibly by reshuffling the roof over the site somewhat. Overall, the evidence derived from structure-reactivity studies of NAG analogues supports the binding of NAG in the way proposed in the present study.
Mapping of the site of CPSI photoaffinity labelling by N-chloroacetyl-L-glutamate supports the proposed mode of NAG binding rCPSI, an enzyme that is functionally virtually identical to hCPSI [45] and which has 94.4 % sequence identity with it [46] , was photoaffinity labelled in its ∼ 16 kDa C-terminal domain with the radioactive and photosensitive NAG analogue [ 14 C]ClNAG [9] . Given its closeness to the methyl group of NAG (Figure 1E ), the -OH group of Thr 1391 appears a good candidate for forming the covalent bond with the NAG radical generated upon irradiationtriggered Cl atom loss [9] . Because of the low efficiency of the labelling (∼ 5 % of enzyme molecules [9] ), direct identification of the labelled residue has not been possible thus far. However, the results of specific protein cleavage techniques agree with the cross-linking of [ 14 C]NAG to Thr 1391 . These studies have been carried out with the 18.9 kDa labelled C-terminal fragment produced by limited proteolysis with the V8 staphylococcal protease (Figures 2A and 2B ), a fragment which was proven by N-terminal sequencing to begin at Met 1329 ( Figure 2B ). Upon CNBr cleavage at methionine residues [35] (Figures 2A and 2C) , the radioactive fragment exhibited an electrophoretic mass of ∼ 17 kDa, as expected ( Figure 2A , second bar) for the fragment that is C-terminal to the most distal methionine, Met 1350 . Upon o-iodosobenzoic treatment to cleave at tryptophan residues [37] (Figures 2A and 2C) , the radioactivity migrated according to a molecular mass, estimated by SDS-urea/PAGE [12] (a suitable technique for small fragments), of 7.3 kDa. This value fits only the mass (7.72 kDa) of the most N-terminal (residues 1329-Trp 1397 ) of the three fragments that should be generated upon cleavage at tryptophan residues (additional two fragments, 1398-Trp 1410 and 1411-1500, with respective masses of 1.4 and 10 kDa). Thus the enzyme is photolabelled upstream of the o-iodosobenzoic cleavage point at Trp 1397 and downstream of the CNBr cleavage point at Met 1350 , in the region between residues 1351 and 1397.
We showed [9] that exhaustive tryptic digestion of [ 14 C]ClNAGlabelled reCPSI yields a single labelled fragment, as indicated by HPLC peptide mapping ( Figure 2D ). The same minimal labelled tryptic peptide was obtained (given the identical elution position of the radioactivity from reversed-phase HPLC, results not shown) by digestion of the whole enzyme and of the 18.9 kDa C-terminal V8 fragment, indicating that this labelled minimal tryptic peptide is contained entirely within the 18.9 kDa Cterminal V8 fragment (as expected, since the enzyme is labelled at some point between residues 1351 and 1397, far from the Nend of the 18.9-kDa V8 fragment). This labelled tryptic peptide behaves in gel filtration [12] as expected for the mass (4.16 kDa) of the minimal tryptic peptide (residues 1388-1424) that contains Thr 1391 (Figures 2A and 2F ). All other minimal tryptic peptides covering the 1351-1397 region (Figure 2A, fourth bar) satisfied by the present experimental evidence ( Figures 2E and  2F ), which reveals: (1) a change in the elution of the radioactive peak from the reversed-phase HPLC column upon V8 digestion of the tryptic fragment; and (2) the elution of this radioactivity from the gel filtration column at the expected position for 0.77 kDa. The only other peptide (residues 1393 to 1414) falling in the 1351-1397 region (the region encompassing the label) that is generated by the V8 protease from the minimal tryptic peptide, has a much larger mass (2.56 kDa) and thus does not fit the gel filtration results. Taken together, all these observations add up to render it highly probable that Thr 1391 is the site of photoaffinity labelling by [ 14 C]ClNAG. We also obtained independent evidence using MS for the labelling by ClNAG of the minimal tryptic peptide encompassing residues 1388-1424. MS fingerprinting with trypsin (see the Experimental section) confirmed the assignment of the 18.9 kDa fragment generated by the V8 protease to the C-terminal domain of the enzyme, and identified the tryptic fragment encompassed between residues 1388 and 1424 by both its mass (calculated mass, 3967.93 Da; experimental mass in two determinations, 3968.24 and 3968.49 Da) and by sequence information obtained by MS/MS. This tryptic peptide was detected ( Figure 2G ) in similar amount (judged from the peak size) both in the fingerprint of the 18.9 kDa fragment generated after control irradiation in the presence of NAG (NAG lacks the Cl substituent and thus it is not photosensitive and does not photolabel the enzyme [9] ) or in the experimental irradiation with ClNAG, in line with the fact that a very small fraction of the protein is labelled with ClNAG [9] . Nevertheless, in the tryptic digest of the sample that was photoaffinity labelled with ClNAG, but not in that in which the ClNAG was replaced by NAG, a small peak was observed with a mass of 4155.94 Da (Figure 2G ), which corresponds, within experimental error, to the expected mass (4155.09 Da) of the 1388-1424 tryptic fragment modified by cross-linking to NAG. The small amount of this peptide, which agrees with the wellknown low-labelling efficiency by ClNAG [9] , prevented further analysis. Nevertheless, the mass of the peak and its exclusive finding in the experimental sample agrees with the conclusion that the 1388-1424 tryptic peptide is the one where ClNAG labelling takes place.
Site-directed mutagenesis studies confirm NAG site identification
Using a baculovirus-based insect cell expression system, we were successful in producing mature rCPSI (that is, the rat liver enzyme lacking the N-terminal mitochondrial targeting sequence) in active form, engineered to incorporate a His 6 tag at its N-terminus for rapid purification. Under optimal expression conditions (see the Experimental section), ∼ 0.5 mg of largely homogeneous ( Figure 3A) active (specific activity, 1.3 + − 0.08 μmol of CP · min −1 · mg −1 ) rCPSI was obtained from 50 ml of culture after a single step of Co 2+ chelation chromatography. The enzyme exhibited normal substrate kinetics (K m values for ATP, HCO 3 − and NH 4 + , 1.06+ − 0.11 mM, 6.43 + − 0.60 mM and 1.07 + − 0.1 mM respectively) and NAG activation kinetics (K a NAG 0.11 + − 0.01 mM, Figure 3A) .
We generated enzyme forms carrying single amino acid mutations affecting NAG site residues predicted to be important for NAG binding. The mutant proteins were produced in the same way and with similar yield and purity as in the case of wild-type CPSI ( Figure 3B) , and appeared well folded (judged from the similarity of their far-UV CD spectra relative to the spectrum of wild-type CPS; results not shown). In agreement with the fact that the catalytic machinery is not provided by the C-terminal domain [10, 13, 20] , all the mutants were active in the presence of NAG, producing CP and ADP with the normal ADP/CP product ratio of 2 (results not shown). However, all mutations significantly increased the concentrations of NAG required for activation ( Figure 3C ), as expected for residues involved in NAG binding. Of particular note was the increase of ∼ 400-fold and ∼ 900-fold in the K a NAG triggered respectively by the T1391V and T1394A mutations, supporting the role of the hydroxy groups of these threonine residues in NAG binding ( Figures 1E and  1F ). The increase of ∼ 70-110-fold in the K a NAG caused by the N1437D and N1440D mutations also agrees with the role of these asparagine residues as hydrogen bond donors to the NAG α-COO − and acetamido carbonyl ( Figures 1E and 1F) . Finally, the W1410K mutation, chosen because it replaces a key pocket roof residue by the highly conserved lysine found at this position in bacterial CPSs, increased the K a NAG ∼ 60-fold ( Figure 3C ). This result is consistent with the observed partial hampering of NAG entry by the Trp 1410 ring (see above). The rate of the enzyme reaction for the T1391V and T1394A mutants, at saturation of NAG, was a third relative to wild-type CPSI ( Figure 3C ), a decrease that appears not to be due to enzyme inactivation, since these mutant rCPSI forms were as stable as wild-type CPS at 4
• C, 25
• C and 37
• C (results not shown). Thus the enzyme-NAG complex appears genuinely less active for these mutants than for the wild-type enzyme, suggesting the involvement of Thr 1391 and Thr 1394 in allosteric signal transmission to the catalytic domains. Since these residues bind to the δ-COO − of NAG ( Figures 1E and 1F) , their involvement in allosteric signal transmission agrees with the previous conclusion [25] that the subsite for δ-COO − is involved in the conformational changes associated with NAG activation.
An unexpected finding of the present study is the observation that the W1410K mutation resulted in a modified specificity for the activator. Thus with this mutant, the affinity was increased when Phe-NAG was used instead of NAG ( Figure 3D ). Phe-NAG was reported [25] and is confirmed in the present study ( Figure 3D ) to activate rCPSI with a K a that is ∼ 2-fold higher than for NAG, but the W1410K mutant binds Phe-NAG considerably better than NAG (respective K a values, 0.55 and 6.3 mM; Figure 3D , insert). As discussed below, this finding, which supports the interaction of the NAG C β atom with Trp 1410 , may have practical implications in the treatment of CPSI deficiency. 
Implications of the present studies for clinical CPSI deficiency
The diagnosis of genetic diseases ideally aims at establishing the disease-causing potential of each amino acid substitution found in a patient presenting the disease, thus excluding that the mutations found could merely be trivial low-frequency polymorphisms having little impact on enzyme functionality or stability. The robust baculovirus expression/purification system developed here provides a well-suited system for carrying out these pathogenicity-testing studies in the case of human CPSI deficiency, and, therefore, can be valuable in the diagnosis and evaluation of this genetic condition. In addition, the present characterization of the NAG site also has practical potential for identifying mutations exclusively affecting NAG activation. A number of amino acid substitutions have been reported already in patients of CPSI deficiency that are candidates to affect NAG regulation, since they fall in the C-terminal domain of the enzyme [47] [48] [49] . We have begun a study aiming at applying the present knowledge to predict the potential effects of these C-terminal domain CPSI mutations, carrying out in parallel expression studies to test the quality of our structure-based predictions. Hopefully, the knowledge of the C-terminal domain structure and on the NAG site will provide in the near future the answer to whether a mutation is likely to impair NAG binding. In such mutations the CPSI catalytic machinery should be intact and it would appear possible, at least in principle, to restore enzyme activity by the administration of large enough doses of NCG [7, 8] . Moreover, our observation that the modified NAG analogue Phe-NAG is a better activator than NAG for W1410K rCPSI suggests that N-carbamoyl-L-β-phenylglutamate would be a better treatment than NCG in the case that a CPSI deficiency patient were found to carry the W1410K mutation. Clearly, our findings raise the novel possibility of synthesizing modified NCG analogues specially tailored to fit individual NAG site mutations for the treatment of CPSI deficiency.
The origin of the NAG site of CPS
Comparison of the structures of the allosteric domains of hCPSI and eCPS reveals that the NAG site of CPSI is topographically equivalent to the site for the relatively poor activator of eCPS, IMP ( Figures 1B, 1C and 1G and Supplementary Figures S1 and S2) . The IMP site of eCPS is an angle-shaped open furrow formed by the same structural elements that also form the NAG site in CPSI ( Figure 1C ). In the bacterial enzyme, the distance between the N-ends of α-helix 4 and the β3-α3 connector is larger than in hCPSI, leaving a space where the purine base of IMP sits. In hCPSI, this space is covered by a roof formed by the mutually stacked bulky side chains of (from outwards to inwards) Lys Background shading in dark and light colours reveals respective invariance or conservative replacement of a given residue in either NAG-sensitive CPSI and CPSIII (dark and light blue), eukaryotic pyrimidine-specific CPSII (red and magenta) or bacterial carB-type CPSs (green and yellow). The following CPSs have been aligned to determine sequence conservations within each class of CPS: CPSI and CPSIII from man, rat, mouse, opossum, chicken (although not ureotelic, chicken has genes for ornithine transcarbamylase and CPSI), bullfrog, zebra fish, the shark Squalus acanthias, the amphioxus Branchiostoma floridae and the sea urchin Strongylocentrotus purpuratus; CPSII from human, hamster, Squalus acanthias, Drosophila melanogaster, the slime mold Dictyostelium discoideum and the ascomycetes Emericella nidulans, Schizosaccharomyces pombe and Saccharomyces cerevisiae; CarB from E. coli, Salmonella typhimurium, Pseudomonas aeruginosa, Serratia protomacularis, Aquifex aeolicus, and pyrimidine-specific CPSs from Bacillus subtilis and Bacillus stearothermophilus. Black and grey shading denotes, respectively, invariance or conservation in at least two CPS families. The dots above and below the CPSI and CarB sequences respectively indicate residues that change their accessibility with NAG (CPSI) or IMP (CarB) binding, using a probe radius of 1.4 Å. Letters above the CPSI sequence show the mutations introduced here. Secondary structure elements of the CPSI and CarB allosteric domains are shown as arrows (β strands) and cylinders (helices) above and below the corresponding sequences. In the CPSI sequence, Thr 1391 , the residue proposed here to be cross-linked to ClNAG upon photoaffinity labelling of the enzyme, is circled. In CAD, a horizontal line underlines the GAGGRR sequence proposed [1] to be involved in the binding of the polyphosphate moiety of the inhibitor UTP. In addition, the serine residue that is phosphorylated by cAMP-dependent protein kinase is indicated [2] . The vertical blue and red lines under the Lys 993 and His 995 of eCPS mark the points of photocross-linking of UMP and IMP respectively to this enzyme [1, 3] . hCPS (in black, residue numbers are labelled in multiples of 10) and eCPS (in green). NAG is represented with carbon atoms in black, in the way it is proposed to be bound to hCPS. IMP bound to eCPS is shown with carbon atoms in green.
Table S1 Synthetic oligonucleotides used in site-directed mutagenesis
The triplets introducing the desired mutations are indicated in bold.
Mutation
Direction Sequence T1391V Forward 5 -GCTTTTTGCCGTAGAAGCCACATCAGAC-3 T1391V
Reverse 5 -GTCTGATGTGGCTTCTACGGCAAAAAGC-3 T1394A
Forward 5 -GCCACAGAAGCCGCATCAGACTGGCTCAACGCC-3 T1394A
Reverse 5 -GTTGGCGTTGAGCCAGTCTGATGCGGCTTCTGTGGC-3 W1410K
Forward 5 -GCCACCCCAGTGGCTAAGCCATCTAGGGAAGGACAG-3 W1410K
Reverse 5 -GGGATTCTGTCCTTCCTGAGATGGCTTAGCCACTGGG-3 N1437D
Forward 5 -GCATTGACCTAGTGATTGACCTCCCCAATAAC-3 N1437D
Reverse 5 -GGTGTTGTTATTGGGGAGGTCAATCACTAGGTC-3 N1440D
Forward 5 -GTGATTAACCTCCCCGATAACAACACCAAATTTG-3 N1440D
Reverse 5 -GACAAATTTGGTGTTGTTATCGGGGAGGTTAATC-3
